To the Editor:
People with Multiple Sclerosis (PwMS) have an over five-fold increased risk of experiencing and being treated for neuropathic pain. Interestingly, pain has been described as a potentially moderating factor of fatigue and depression [1] . Up to 92% of PwMS are affected by fatigue [2] and 24% suffer from depression [3] . Depressed PwMS are more likely to have pain and there is a positive association between the interference of painful symptoms, and pain severity, with depression severity [4] . Pain, fatigue, and depression are interdependently associated and potentially modifiable [5] . Thus, improving pain symptoms may improve fatigue and depression, which would contribute to an improved quality of life. Conceptually, the study of this MS symptom cluster (pain, fatigue, depression) recognizes that symptoms occur concurrently and that co-occurring symptoms may provide an efficient target for assessment and management. The question at hand is -what is the best treatment for this MS symptom cluster? One possible modality is transcranial direct current stimulation (tDCS). To date, no study has investigated the effects of tDCS to improve this MS symptom cluster.
We conducted a double blind, sham-controlled, and randomized crossover pilot study. Six moderately disabled PwMS (relapsingremitting MS; 3 female; age ¼ 46.7 ± 14.1 yrs.) completed two randomly ordered blocks of stimulation (tDCS or sham). Each block involved five daily sessions. At the first visit, participants completed the, Fatigue Severity Scale (FSS), visual analog scale for pain (VAS), and Beck Depression Inventory (BDI) questionnaires. Isokinetic leg strength and fatigue testing were also performed. Leg strength was determined via five sets of one isokinetic maximal flexion and extension (60 /s) and objectively defined the more-affected leg. A tDCS device (Soterix Medical Inc., New York, NY) delivered a small direct current through two surface sponge electrodes (5 cm Â 7 cm, soaked with 15 mM NaCL). The anode was placed over the M1 representation of the more-affected leg and the cathode was placed over the contralateral supraorbit. The isokinetic fatigue test (FT) involved 40 continuous maximal contractions (concentric/concentric, 120 /s) of the knee extensors and flexors. The FT was performed using the weaker (more-affected) leg. The peak work of each repetition was used to calculate the fatigue index (FI-W) as follows: (total work performed in the last half/total work performed in the first half) * 100. The stimulation blocks (tDCS or sham) were performed in a randomized order. For tDCS, the participants received 2 mA of stimulation for 20 min while seated comfortably and quietly. The intensity started at 0 mA and incrementally increased to 2mA. At minute 20, the current was gradually reduced from 2 mA to 0 mA. The sham block was identical to the tDCS block, except the participants only received the initial ramp-up to 2 mA, after which the current was set to 0 mA. In days 2e4, participants only received tDCS. In day 5, participants completed the FSS, VAS, and BDI questionnaires, and repeated the isokinetic fatigue test. Block 2 was performed in the same manner as Block 1, but stimulation shifted to either tDCS or sham. Paired t-tests and effect sizes (Cohen's d) were used to compare the effects of tDCS after five days.
Five days of tDCS resulted in less knee extensor fatigability (FI- (Table  1) . This is the first pilot study targeting the MS symptom cluster of pain, fatigue, and depression with a single-treatment approach (tDCS). Sham stimulation did not affect the MS symptom cluster, indicating that improvements were tDCS-specific.
Our results showed that five days of 2 mA tDCS applied over M1 improved performance fatigability (FI-W), perceived fatigue (FSS), and pain (VAS). Previous 'single-symptom' studies have shown that tDCS was effective in improving MS-related fatigue [6, 7] and reducing central neuropathic pain in PwMS [8] . Tecchio et al. [6] found that five days of 1.5 mA tDCS over the bilateral whole body somatosensory area was effective at improving MS fatigue. Ferrucci et al. [7] also showed improvements from five days of 1.5 mA tDCS over M1 on perceived fatigue in PwMS. Our study expands these findings and showed improvements in performance fatigability (FI-W), perceived fatigue (FSS), and pain (VAS) after five daily sessions. The mechanisms underscoring the effects of anodal tDCS on fatigue could be related to an increased M1 cortical excitability, which reduces supraspinal fatigue and ratings of perceived exertion [9] . An increased corticospinal excitability, together with alterations in motor unit recruitment, could theoretically explain the observed improvements in performance fatigue [9] . 
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Brain Stimulation j o u r n a l h o m e p a g e : h t t p : / / w w w . j o u r n a l s . e l se v i e r . c o m / b r a i n -s t i m u l a t i o n tDCS reduced pain in PwMS in our study. This agrees with Mori et al. [8] who also found improvements in pain after five daily sessions of 2 mA tDCS over M1. The effects of tDCS on the specific brain networks involved in pain processing are poorly understood. However, it has been reported that tDCS causes polarity-dependent shifts of the resting membrane potential and might consequently change neuronal excitability at the site of stimulation and functionally connected areas. As revealed by our recent study [10] , 2 mA tDCS at M1 induced remote effects in pain-related structures, like the thalamus. The role of the thalamus in modulating pain is well described and suggests that tDCS can modulate sensory discriminative (lateral pain pathway) and affective-motivational (medial pain pathway) components of the pain system [10] . Lastly, tDCS has well-accepted antidepressant effects, but depression was unchanged in this study. It may be that because our participants had no depression or mild mood disturbance (BDI scores < 17), the effects of tDCS on this part of the symptom cluster were minimal.
This pilot study underscores that tDCS is a promising tool for the treatment of the MS symptom cluster of pain, fatigue, and depression. More studies are needed to test the efficacy of tDCS in larger samples, more disabled (and more depressed) PwMS, different stimulation parameters, possible short-and long-term side effects, and provide deeper insight into mechanisms underpinning tDCSrelated changes.
